AbbVie, U.S. Government Strike Deal to Expand Access and Invest in Domestic Pharma

AbbVie and the Trump administration announced a three-year agreement to boost U.S. access and affordability: AbbVie will offer low Medicaid prices, expand direct-to-patient access via the TrumpRx program for medicines including ALPHAGAN, COMBIGAN, HUMIRA and SYNTHROID, and commit $100 billion in U.S.-based R&D and manufacturing investments over the next decade, in exchange for tariff relief and exemption from future price mandates; the deal aims to address all four of the President's drug pricing priorities, with terms kept confidential.